Injection Pen Global Market Report 2024

Injection pens are utilized to administer medication beneath the skin. They offer a more convenient and user-friendly method for delivering injectable medications like insulin, thereby enhancing patient compliance. These pens typically comprise a cartridge, a dosage measurement dial, and a disposable needle, providing a simpler, more accurate, and convenient alternative to using a vial and syringe.

The primary categories of injection pens include disposable and reusable variants. Disposable injection pens feature a non-replaceable prefilled cartridge that is discarded after use. On the other hand, reusable injection pens come with a replaceable cartridge that can be swapped out. Injection pens find application in a range of medical purposes, including diabetes, fertility treatments, osteoporosis, growth hormone therapy, and other therapies. They are employed by various end-users, including home care settings, hospitals, and clinics.

The injection pen market research report is one of a series of new reports that provides injection pen market statistics, including injection pen industry, global injection pen market size, regional shares, competitors with injection pen market share, detailed injection pen market segments, market trends and opportunities, and any further data you may need to thrive in the injection pen industry. This injection pen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The injection pen market size has grown strongly in recent years. It will grow from $53.79 billion in 2023 to $58.57 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth observed in the historical period can be attributed to several factors. These include an increased need for effective diabetes management, a growing preference among patients for injection pens, a reduction in needle phobia, improved accuracy in dosage administration, as well as a rise in the aging population. These factors collectively contributed to the growth of the injection pen industry during that period.

The injection pen market size is expected to see strong growth in the next few years. It will grow to $85.75 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to various factors, including the increasing prevalence of diabetes, a rise in the demand for biologics and biosimilars, a growing need for personalized medicine, the requirement for home healthcare solutions, and the expanding presence of emerging markets. Moreover, significant trends expected in the forecast period encompass the development of smart injection pens, the integration of digital health technologies, the incorporation of wearable devices, enhancements in user interface design, and compatibility with autoinjectors. These trends are poised to shape the future of the injection pen industry.

The growth of the injection pen market is being fueled by the increasing prevalence of diseases like diabetes and arthritis. Factors such as the expanding population affected by obesity, sedentary lifestyles, unhealthy dietary habits, and advancing age have contributed to the global rise in diabetes cases. According to the International Diabetes Federation (IDF), it is projected that the global population with diabetes will reach approximately 640 million by 2040. In emerging countries like India, around 69 million individuals have diabetes, and this number is anticipated to climb to 100 million by 2030. Consequently, the surge in diseases like diabetes and arthritis is expected to be a driving force for the injection pen market.

The escalating prevalence of obesity is set to boost the growth of the injection pens market. Obesity, a condition characterized by excessive body fat leading to detrimental health effects, necessitates precise and adjustable dosing through injection pens for medications like insulin. This ensures accurate delivery in specific areas of the body, especially relevant for individuals dealing with obesity. For instance, data from the Government Digital Service in the UK indicated that the projected obesity rate for individuals aged 18 and above in England was 25.9% for 2021–2022, reflecting a 25.2% increase. Therefore, the rising prevalence of obesity is a significant factor propelling the growth of the injection pens market.

Technological advancements represent a notable trend in the injection pen market. Companies in this sector are prioritizing product innovation and the development of efficient delivery systems. These technological strides facilitate precise medication delivery, enhance patient satisfaction and adherence, and improve overall usability. For instance, in September 2022, Medtronic, a US-based medical technology company, introduced InPen integrated with real-time Guardian Connect CGM data. This integrated solution consolidates crucial diabetes management information, including real-time glucose levels and insulin dosing, into a single screen, simplifying decision-making for users.

Major players in the injection pen market are dedicated to introducing innovative products like Wegovy to provide dependable services to customers. Wegovy, administered through an injection pen, is designed for treating patients dealing with obesity and weight loss. In September 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy. This injection pen contains the drug semaglutide, assisting patients in achieving a body weight reduction of approximately 15% when combined with exercise and lifestyle modifications.

In September 2023, Abbott Laboratories, a US-based medical devices company, acquired Bigfoot Biomedical Inc., bolstering its presence in the diabetes care sector with advanced glucose monitoring technology. This strategic move aims to develop user-friendly, cost-effective tools for individuals managing diabetes. Bigfoot Biomedical Inc., headquartered in California, is a medical technology company specializing in smart injection pens.

Major companies operating in the injection pen market include Novo Nordisk A/S, Ypsomed Holding AG, Sandoz Inc., Eli Lilly and Company, Merck KGaA, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Owen Mumford Ltd., Sulzer Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Lupin Ltd., Wockhardt Ltd., AptarGroup Inc., Novartis AG, Gerresheimer AG, SHL Medical AG, Boehringer Ingelheim International GmbH, Nemera France SA, Companion Medical Inc., Jiangsu Delfu Medical Devices Co. Ltd., Haselmeier GmbH, GlaxoSmithKline plc., Stat Medical Devices Inc., DuPont de Nemours Inc., Emperra GmbH E-Health Technologies, Biocon Limited, Becton Dickinson and Company, Mylan N.V., Terumo Corporation, West Pharmaceutical Services Inc., Bespak Europe Ltd., Mitsubishi Gas Chemical Company Inc., Nipro Corporation, Zogenix Inc., Consort Medical plc

North America was the largest region in the injection pen market in 2023. The regions covered in the injection pen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the injection pen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The injection pen market consists of sales of disposable injection pens and reusable injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.